≥18 years of age 2. Provided signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses. 3. Resolved acute effects of any prior therapy to baseline severity or ≤Grade 1 NCI CTCAE except for AEs not constituting a safety risk by investigator judgment. 4. Have a histologically or cytologically documented advanced solid tumor that has relapsed from or is refractory to standard treatment, or for which no standard treatment is available. Note: patients with certain tumor types such as those with relatively high prevalence of DDR gene mutations and/or PTGR1 over expression (e.g., triple negative breast cancer, prostate, ovarian, pancreatic, bladder, and GBM) may be preferentially enrolled in Phase 1A. 5. ECOG performance status 0-1 or Karnofsky performance scale >60 for GBM patients. 6. Patients must have measurable disease per RECIST 1.1 (Appendix 3) or RANO (Appendix 4) criteria as applicable. Note: patients without measurable disease may be eligible, following discussion with the investigator and the sponsor, if the patient presents with non-measurable but evaluable disease of any size unequivocally attributable to advanced solid tumor. 7. Patients must have life expectancy >3 months. 8. Adequate organ function at screening defined as: • Liver Function − AST, ALT ≤3× ULN or 2.0 cm on screening contrast brain MRI, discussion with and approval from the medical monitor is required prior to enrollment. • Previously treated brain metastases. Note: Brain metastases previously treated with local therapy is either stable since treatment or progressed since prior local CNS therapy, BUT there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator. Patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) are eligible with discussion and approval by the medical monitor. Complion Document ID: 6664154 Lantern Pharma Inc Protocol LTRN184-1AST23-1 Confidential Page 44 of 84 Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during study screening are eligible to enroll if all of the following criteria are met: • Time since whole brain radiation therapy was ≥21 days prior to first dose of LP-184, • Time since stereotactic radiosurgery was ≥7 days prior to first dose of LP-184, or • Time since surgical resection was ≥28 days. • Other sites of disease assessable by RECIST v1.1 are present

Exposure to anti-cancer therapy within 2 weeks or within at least 5 half-lives whichever is shorter; or 4 weeks from any biologics/immunotherapies or any investigational therapy prior to the first dose of LP-184. Note: Low dose steroids (oral prednisone or equivalent ≤20 mg/day), localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion if such therapy has not been changed within 4 weeks before LP-184 treatment. 2. History of retinopathy and/or macular degeneration. 3. Has received radiation within 4 weeks of Cycle 1 Day 1. 4. Have acute and severe bacterial, viral, or fungal infection. 5. Known or demonstrated viral infection as listed below: a. Seropositivity for HIV (only if required by local regulations). b. Hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen or antibody to hepatitis C virus with confirmatory testing). 6. Are pregnant or breastfeeding. 7. Have clinically significant cardiac disease including: − New York Heart Association Class IV heart failure. − Myocardial infarction or stroke ≤3 months prior to the first dose of LP-184. − Unstable angina within ≤12 weeks prior to the first dose of LP-184 unless the underlying disease has been corrected by procedural intervention e.g., stent, bypass. − Severe aortic stenosis. − Uncontrolled arrhythmia. Sponsor approval of patients with arrhythmia is required. − QTc >470 ms by Fredericia criteria. Complion Document ID: 6664154 Lantern Pharma Inc Protocol LTRN184-1AST23-1 Confidential Page 45 of 84 − Congenital long QT syndrome, or a QT interval corrected by Fridericia’s formula (QTcF) >470 ms (average of triplicate ECGs) at Screening and/or on Cycle 1 Day 1 (pre-dose) except for a documented bundle branch block or unless secondary to pacemaker. In the case of a documented bundle branch block or a pacemaker, discussion with the medical monitor is required prior to enrollment. 8. Have clinically significant AEs that have not returned to baseline or ≤Grade 1 based on NCI-CTCAE unless approved by the sponsor. Patients with chronic Grade 2 toxicities may be eligible per the discretion of the investigator and sponsor (e.g., Grade 2 chemotherapy-induced neuropathy or hypothyroidism from prior immunotherapy treatment). 9. Have had major surgery (requiring general anesthesia) within ≤4 weeks of first dose of LP-184. 10. Have any other serious medical condition which, in the opinion of the investigator, would preclude the patient from study participation. 11. Have clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Patients with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 3 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (1 week for stereotactic radiotherapy). 12. For patients with CNS metastatic disease, based on screening brain MRI, patients must not have: • Any untreated brain lesions >2.0 cm in size, unless medical monitor approved enrollment. • Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of >2 mg of dexamethasone (or equivalent). • Patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) are eligible with discussion and approval by the medical monitor. • Any brain lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where an increase in size or possible treatment-related edema may pose a risk to the patient (e.g., brain stem lesions). Patients who underwent local treatment for such lesions identified by screening contrast brain MRI may still be eligible based on criteria described under CNS inclusion criteria described above. • Known or suspected leptomeningeal disease as documented by the investigator.